New drug cocktail aims to wipe out breast cancer before surgery

NCT ID NCT06178159

Recruiting now Disease control Sponsor: RemeGen Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a combination of three drugs—disitamab vedotin, pertuzumab, and toripalimab—can shrink or eliminate HER2-positive breast tumors before surgery. About 40 adults with early-stage breast cancer will receive the drugs intravenously for 18 weeks, then have surgery. The main goal is to see if the cancer is completely gone at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: disitamab vedotin, pertuzumab, and toripalimab (drugs given intravenously)
What this could lead to: If successful, this could lead to a more effective pre-surgery treatment for HER2-positive breast cancer, potentially improving the chance of eliminating all cancer before surgery.
What could go wrong: This is an early Phase 2 trial with only 40 participants, so results may not apply to all patients. The combination of drugs may cause side effects, and it is not yet known if it works better than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.